Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 15, 2023
March 02 2023 - 8:30AM
Business Wire
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the
Company”), an experienced and innovative biotechnology company
committed to transforming people’s lives by silencing diseases
through precision engineered medicines, today announced that the
Company will release its financial and business results for the
fourth quarter and full year ended December 31, 2022, on Wednesday,
March 15, 2023.
Management will host a conference call at 8:00 a.m. EDT / 12:00
p.m. GMT that day to discuss the Company’s financial results and
provide a general business update. The conference call will be
webcast live and available on the Investors section of the Silence
website at www.silence-therapeutics.com. The webcast will also be
archived on the Company’s website.
Details of the webcast and conference call:
Webcast link:
https://edge.media-server.com/mmc/p/7vduw4ku
Conference call registration link:
https://register.vevent.com/register/BIbe6ada25ddb74c528acb36048aec7227
About Silence Therapeutics Silence Therapeutics is
developing a new generation of medicines by harnessing the body's
natural mechanism of RNA interference, or RNAi, to inhibit the
expression of specific target genes thought to play a role in the
pathology of diseases with significant unmet need. Silence's
proprietary mRNAi GOLD™ platform can be used to create siRNAs
(short interfering RNAs) that precisely target and silence
disease-associated genes in the liver, which represents a
substantial opportunity. Silence's wholly owned product candidates
include SLN360 designed to address the high and prevalent unmet
medical need in reducing cardiovascular risk in people born with
high levels of lipoprotein(a) and SLN124 designed to address
hematological diseases. Silence also maintains ongoing research and
development collaborations with AstraZeneca, Mallinckrodt
Pharmaceuticals, and Hansoh Pharma, among others. For more
information, please visit
https://www.silence-therapeutics.com/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230301005424/en/
Enquiries:
Silence Therapeutics plc Gem Hopkins, Head of IR
and Corporate Communications ir@silence-therapeutics.com Tel: +1
(646) 637-3208
Silence Therapeutics (NASDAQ:SLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Silence Therapeutics (NASDAQ:SLN)
Historical Stock Chart
From Jul 2023 to Jul 2024